Inventor · Brisbane, CA, US

Nathaniel David

44Patents
11h-index
26Co-inventors
75Inventor score

Filing activity: Jun 8, 2001 → Aug 7, 2023

Most-cited inventions

PatentTitleAreaCited byStatus
US6872250B2 Microvolume crystallization method employing multiple lumens Emerging Cross-Sectional Technologies 94 Expired
US9849128B2 Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells Chemistry; Metallurgy 23 Active
US8242294B2 Synthetic bile acid compositions and methods Emerging Cross-Sectional Technologies 20 Active
US6719840B2 In situ crystal growth and crystallization Emerging Cross-Sectional Technologies 20 Expired
US10010546B2 Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Chemistry; Metallurgy 19 Active
US9050349B2 Synthetic bile acid compositions and methods Emerging Cross-Sectional Technologies 15 Active
US8546367B2 Synthetic bile acid compositions and methods Emerging Cross-Sectional Technologies 15 Active
US8461140B2 Synthetic bile acid compositions and methods Emerging Cross-Sectional Technologies 15 Active
US8883770B2 Synthetic bile acid compositions and methods Chemistry; Metallurgy 15 Active
US10195213B2 Chemical entities that kill senescent cells for use in treating age-related disease Human Necessities 13 Active
US9636349B2 Synthetic bile acid compositions and methods Emerging Cross-Sectional Technologies 13 Active
US9855266B2 Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline Chemistry; Metallurgy 11 Active
US9993472B2 Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 Chemistry; Metallurgy 9 Active
US9987291B2 Synthetic bile acid compositions and methods Emerging Cross-Sectional Technologies 7 Active
US10328073B2 Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells Chemistry; Metallurgy 6 Active
US9980962B2 Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease Chemistry; Metallurgy 6 Active
US10328058B2 Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques Chemistry; Metallurgy 5 Active
US10258618B2 Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen Chemistry; Metallurgy 5 Active
US10213426B2 Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population Chemistry; Metallurgy 4 Active
US10478432B2 Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye Chemistry; Metallurgy 4 Active
US10413542B2 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase Chemistry; Metallurgy 4 Active
US9522155B2 Synthetic bile acid compositions and methods Chemistry; Metallurgy 4 Active
US10130628B2 Treatment of joint pain Chemistry; Metallurgy 3 Active
US10478433B2 Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss Chemistry; Metallurgy 3 Active
US10517866B2 Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor Chemistry; Metallurgy 3 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.